Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Translocator Protein (TSPO) Genetic Polymorphism A147T is Associated with Worse Survival in Male Glioblastoma Patients

Version 1 : Received: 2 August 2021 / Approved: 5 August 2021 / Online: 5 August 2021 (10:22:34 CEST)

A peer-reviewed article of this Preprint also exists.

Troike, K.M.; Acanda de la Rocha, A.M.; Alban, T.J.; Grabowski, M.M.; Otvos, B.; Cioffi, G.; Waite, K.A.; Barnholtz Sloan, J.S.; Lathia, J.D.; Guilarte, T.R.; Azzam, D.J. The Translocator Protein (TSPO) Genetic Polymorphism A147T Is Associated with Worse Survival in Male Glioblastoma Patients. Cancers 2021, 13, 4525. Troike, K.M.; Acanda de la Rocha, A.M.; Alban, T.J.; Grabowski, M.M.; Otvos, B.; Cioffi, G.; Waite, K.A.; Barnholtz Sloan, J.S.; Lathia, J.D.; Guilarte, T.R.; Azzam, D.J. The Translocator Protein (TSPO) Genetic Polymorphism A147T Is Associated with Worse Survival in Male Glioblastoma Patients. Cancers 2021, 13, 4525.

Journal reference: Cancers 2021, 13, 4525
DOI: 10.3390/cancers13184525

Abstract

Glioblastoma (GBM) is the most common primary brain tumor in adults, with few available therapies and a 5-year survival rate of 7.2%. Hence, strategies for improving GBM prognosis are urgently needed. The translocator protein 18kDa (TSPO) plays crucial roles in essential mito-chondria-based physiological processes and is a validated biomarker of neuroinflammation, which is implicated in GBM progression. The TSPO gene has a germline single nucleotide pol-ymorphism, rs6971, which is the most common SNP in the Caucasian population. High TSPO gene expression is associated with reduced survival in GBM patients; however, the relation between the most frequent TSPO genetic variant and GBM pathogenesis is not known. The present study ret-rospectively analyzed the correlation of the TSPO polymorphic variant rs6971 with overall and progression-free survival in GBM patients using three independent cohorts. TSPO rs6971 poly-morphism was significantly associated with shorter overall survival and progression-free survival in male GBM patients but not in females in one large cohort of 441 patients. We observed similar trends in two other independent cohorts. These observations suggest that the TSPO rs6971 pol-ymorphism could be a significant predictor of poor prognosis in GBM, with a potential for use as a prognosis biomarker in GBM patients. These results reveal for the first time a biological sex-specific relation between rs6971 TSPO polymorphism and GBM.

Keywords

Glioblastoma; biomarker; TSPO; single nucleotide polymorphism; survival.

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.